TAKE16.78

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹248 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
TAKE
FY26
VIMTALABS
FY24
SUVEN
FY26
Peer
Median
Valuation — at last close
P/E22.68×34.49×34.49× -34%
P/B7.99×4.43×16.05×10.24× -22%
EV/EBITDA-129.54×16.38×-33.34×-8.48× -1427%
Market Cap₹248 Cr₹1,416 Cr₹9,494 Cr₹5,455 Cr -95%
Growth
Revenue CAGR 3Y-34.07%14.74%-19.30%-2.28% -1394%
Revenue CAGR 5Y-41.25%8.40%-12.00%-1.80% -2192%
Net Income CAGR 3Y24.20%24.20%
Revenue YoY (latest Q)73981.22%10.09%91.02%50.55% +146238%
Net Income YoY (latest Q)216.76%112.16%-147.71%-17.78% +1319%
Profitability
EBITDA Margin-3.53%27.27%-3998.80%-1985.77% +100%
Net Income Margin20.02%12.89%-3884.13%-1935.62% +101%
Return on Common Equity35.00%12.83%-46.73%-16.95% +306%
Return on Capital Employed-6.20%15.20%-48.90%-16.85% +63%
Return on Assets29.94%10.25%-44.27%-17.01% +276%
Credit & Quality
Total Debt/Equity0.00×0.06×0.00×0.03× -100%
Interest Coverage-5.51×24.79×-1838.51×-906.86× +99%
Scale — latest FY
Revenue / Total Income₹54.2 Cr₹318 Cr₹7.1 Cr₹163 Cr -67%
Net Income₹10.8 Cr₹41 Cr−₹276 Cr−₹118 Cr +109%
Total Assets₹36.2 Cr₹400 Cr₹624 Cr₹512 Cr -93%
EPS₹0.74₹18.51₹-12.13₹3.19 -77%
Book Value per Share₹2.1₹144.2₹22.43₹83.32 -97%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.